3439-02-9

Usage

Uses

Used in Chemical Synthesis:
4-BROMOFURAN-2-CARBOXYLICACID is used as a key intermediate in the synthesis of various organic compounds and pharmaceuticals. Its distinctive bromine atom and carboxyl group enable it to participate in a range of chemical reactions, making it a valuable building block for the development of new molecules with potential applications in various industries.
Used in Research and Development:
4-BROMOFURAN-2-CARBOXYLICACID is employed as a research compound in academic and industrial laboratories. Its unique structural features allow scientists to explore its reactivity, stability, and potential applications in the synthesis of novel compounds. Additionally, it can be used as a reference material for studying the properties of related furan derivatives and their analogs.
Used in Pharmaceutical Industry:
4-BROMOFURAN-2-CARBOXYLICACID is used as a starting material or intermediate in the synthesis of pharmaceutical compounds. Its bromine atom and carboxyl group can be further modified or functionalized to create new drug candidates with potential therapeutic applications. 4-BROMOFURAN-2-CARBOXYLICACID's unique structure may also contribute to the development of targeted drug delivery systems or prodrugs that can be activated in specific biological environments.
Used in Agrochemical Industry:
4-BROMOFURAN-2-CARBOXYLICACID is utilized as a building block in the synthesis of agrochemicals, such as pesticides and herbicides. Its distinctive structural features can be exploited to create new molecules with improved efficacy, selectivity, and environmental compatibility. 4-BROMOFURAN-2-CARBOXYLICACID's reactivity and stability may also contribute to the development of novel agrochemical formulations with enhanced performance and reduced environmental impact.

Upstream product

• 32460-04-1 3,4-dibromo-furan-2-carboxylic acid 
• 2434-03-9 4,5-dibromo-2-furoic acid 
• 21921-76-6 4-bromo-2-furancarbaldehyde 

Downstream Products

• 4805-95-2 4-bromo-5-nitro-furan-2-carboxylic acid 
• 86471-28-5 4-phenylfuroic acid 
• 58777-59-6 4-bromo-furan-2-carbonyl chloride 
• 1007197-77-4 4-(4-chlorophenyl)furan-2-carboxylic acid 
• 1257792-60-1 (Z)-4-(2-hydroxy-3-{N'-[3-methyl-5-oxo-1-(5,6,7,8-tetrahydronaphthalen-2-yl)-1,5-dihydropyrazol-4-ylidene]hydrazino}phenyl)furan-2-carboxylic acid 
• 1257792-76-9 4-(3-amino-2-hydroxyphenyl)furan-2-carboxylic acid hydrobromide 
• 1257792-75-8 4-(3-amino-2-methoxyphenyl)furan-2-carboxylic acid 
• 1333376-26-3 C₂₁H₂₁NO₂ 
• 1333376-25-2 C₁₄H₁₄O₃ 

Relevant academic research and scientific papers

Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase

Two principal neurotransmitters are involved in the regulation of mammalian neuronal activity, namely, γ-aminobutyric acid (GABA), an inhibitory neurotransmitter, and l-glutamic acid, an excitatory neurotransmitter. Low GABA levels in the brain have been implicated in epilepsy and several other neurological diseases. Because of GABA's poor ability to cross the blood-brain barrier (BBB), a successful strategy to raise brain GABA concentrations is the use of a compound that does cross the BBB and inhibits or inactivates GABA aminotransferase (GABA-AT), the enzyme responsible for GABA catabolism. Vigabatrin, a mechanism-based inactivator of GABA-AT, is currently a successful therapeutic for epilepsy, but has harmful side effects, leaving a need for improved GABA-AT inactivators. Here, we report the synthesis and evaluation of a series of heteroaromatic GABA analogues as substrates of GABA-AT, which will be used as the basis for the design of novel enzyme inactivators.

Thiadiazole amide compound and application thereof

The invention discloses a thiadiazole amide compound and application thereof, and belongs to the field of medicines. The structural general formula of the compound is shown as a formula (I) and is a novel compound with androgen receptor antagonistic activity, wherein one of the key targets is a binding pocket between the androgen receptor ligand binding domain dimer interface. The compound provided by the invention has high activity for antagonizing the transcription of androgen receptor and is at the molecular level. The cell level and the animal level all show good biological activity, and have better safety. , The invention can be applied to the preparation of drugs for treating androgen receptor abnormal expression tumors, including but not limited to prostate cancer, metastatic prostate cancer, castration-resistant prostate cancer, breast cancer and ovarian cancer.

BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES PHARMACEUTCIAL SALTS, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

The present invention relates to bicyclo-substituted pyrazolon azo derivatives pharmaceutical acceptable salts of formula (I), methods for their preparation, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor. The definition of substituents in formula (I) are the same as the description.

SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF

The present invention relates to novel substituted furancarboxamides, methods for their production, their use for the treatment and/or prevention of diseases, as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially retroviral diseases, in humans and/or animals.

SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF

The present invention relates to pharmaceutically acceptable salts of bicycle-substituted pyrazolon azo derivatives represented by general formula (I), methods for their preparation, pharmaceutical compositions comprising the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics, and their use as agonists of thrombopoietin receptor. The definitions of substituents in general formula (I) are the same as the description.

SAR analysis of innovative selective small molecule antagonists of sphingosine-1-phosphate 4 (S1P4) receptor

Recent evidence suggests an innovative application of chemical modulators targeting the S1P4 receptor as novel mechanism-based drugs for the treatment of influenza virus infection. Modulation of the S1P4 receptor may also represent an alternative therapeutic approach for clinical conditions where reactive thrombocytosis is an undesired effect or increased megakaryopoiesis is required. With the exception of our recent research program disclosure, we are not aware of any selective S1P4 antagonists reported in the literature to date. Herein, we describe complementary structure-activity relationships (SAR) of the high-throughput screening (HTS)-derived hit 5-(2,5-dichlorophenyl)-N-(2,6-dimethylphenyl)furan-2- carboxamide and its 2,5-dimethylphenyl analog. Systematic structural modifications of the furan ring showed that both steric and electronic factors in this region have a significant impact on the potency. The furan moiety was successfully replaced with a thiophene or phenyl ring maintaining potency in the low nanomolar range and high selectivity against the other S1P receptor subtypes. By expanding the molecular diversity within the hit-derived class, our SAR study provides innovative small molecule potent and selective S1P 4 antagonists suitable for in vivo pharmacological validation of the target receptor.

FUSED PYRAZINE COMPOUNDS AS THEIR SALTS, USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel salts of a [1.2.4]triazolo[1,5-a]pyrazine compound according to Formula I: The salts may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, and others.

BITTER TASTE MODULATORS

The present invention includes antagonists of human type 2 taste receptors (hT2Rs) having structural Formula (I). The present invention also provides compositions containing these antagonists, the use of these antagonists for modulating taste perception, particularly bitter taste, and the method of preparing these antagonists (I).

SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS

Described herein are compounds useful as antagonists of sphingosine-1-phosphate receptors. Further described herein is the use of these compounds and related pharmaceutical compositions to treat disorders associated with sphingosine-1-phosphate-3 (S1P3) r

SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS

Described herein are compounds of the formula useful as antagonists of sphingosine-1- phosphate receptors. Further described herein is the use of these compounds and related pharmaceutical compositions to treat disorders associated with sphingosine-1 -pho